Today, Jefferies Group Reiterates “$80.00” Price Target for Bluebird Bio Inc. (BLUE)

Today, Jefferies Group Reiterates “$80.00” Price Target for Bluebird Bio Inc. (BLUE)

Jefferies Group set a $80.00 price objective on Bluebird Bio Inc. (NASDAQ:BLUE) in a research report released on Thursday morning. The brokerage currently has a buy rating on the stock.

A number of other analysts have also recently weighed in on the stock. Roth Capital started coverage on shares of Bluebird Bio in a report on Thursday, September 22nd. They set a buy rating and a $87.00 price objective on the stock. Goldman Sachs Group Inc. raised shares of Bluebird Bio from a buy rating to a conviction-buy rating and set a $135.00 price objective on the stock in a report on Thursday, September 15th. Cantor Fitzgerald cut shares of Bluebird Bio from a hold rating to a sell rating and cut their target price for the company from $65.24 to $37.00 in a report on Friday, October 14th. Leerink Swann lifted their target price on shares of Bluebird Bio from $67.00 to $80.00 and gave the company an outperform rating in a report on Friday, October 14th. Finally, Maxim Group reaffirmed a buy rating and issued a $85.00 target price (down from $105.00) on shares of Bluebird Bio in a report on Thursday, August 4th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $82.82.

Bluebird Bio (NASDAQ:BLUE) opened at 60.65 on Thursday. The stock’s market capitalization is $2.26 billion. Bluebird Bio has a 12-month low of $35.37 and a 12-month high of $90.01. The firm’s 50-day moving average is $55.97 and its 200 day moving average is $53.04.

Bluebird Bio (NASDAQ:BLUE) last released its quarterly earnings data on Wednesday, November 2nd. The company reported ($2.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.59) by $0.48. Bluebird Bio had a negative return on equity of 30.79% and a negative net margin of 3,941.72%. The company had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.82 million. During the same period in the previous year, the business posted ($1.18) EPS. The firm’s revenue for the quarter was up 17.4% compared to the same quarter last year. Equities analysts expect that Bluebird Bio will post ($7.05) EPS for the current year.

In related news, insider Eric Sullivan sold 416 shares of the business’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $67.00, for a total value of $27,872.00. Following the sale, the insider now directly owns 5,891 shares in the company, valued at approximately $394,697. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 3.50% of the stock is currently owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its stake in Bluebird Bio by 37.7% in the third quarter. Price T Rowe Associates Inc. MD now owns 3,365,797 shares of the company’s stock valued at $228,134,000 after buying an additional 921,416 shares in the last quarter. Cornerstone Capital Management Holdings LLC. raised its stake in Bluebird Bio by 143.8% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 7,800 shares of the company’s stock valued at $528,000 after buying an additional 4,600 shares in the last quarter. Credit Suisse AG raised its stake in Bluebird Bio by 9.3% in the third quarter. Credit Suisse AG now owns 101,322 shares of the company’s stock valued at $6,869,000 after buying an additional 8,656 shares in the last quarter. Chartwell Investment Partners LLC acquired a new stake in Bluebird Bio during the third quarter valued at approximately $2,830,000. Finally, Baker BROS. Advisors LP acquired a new stake in Bluebird Bio during the third quarter valued at approximately $19,923,000.

Bluebird Bio Company Profile

Related posts

Leave a Comment